歡迎來到上海通蔚!

021-54845833/15800441009

品質(zhì)保證 · 通蔚試劑

當(dāng)前位置: 首頁 > 科研產(chǎn)品 > 科研抗體 > 一抗 > 兔抗NLRP3多克隆抗體
  • 兔抗NLRP3多克隆抗體

    規(guī)格:
    數(shù)量:

    購買數(shù)量

    價(jià)格:
    • 品牌 : 通蔚生物
    • 目錄號(hào) : TW20859
    • 應(yīng)用 : 僅供科研使用
    • 保存條件 : 低溫保存
    • 貨期 : 現(xiàn)貨
    • 商品庫存:80
  • 商品詳情
  • 參考文獻(xiàn)
  • 說明書下載
  • 商品評(píng)論0
  • 相關(guān)產(chǎn)品

中文名稱: 兔抗NLRP3多克隆抗體


英文名稱: Anti-NLRP3 rabbit polyclonal antibody


別      名: AII; AVP; FCU; MWS; FCAS; CIAS1; NALP3; C1orf7; CLR1.1; PYPAF1; AGTAVPRL


儲(chǔ)      存: 冷凍(-20℃)


宿      主: Rabbit


抗      原: NLRP3


相關(guān)類別: 一抗


反應(yīng)種屬: Human


標(biāo)   記 物: Unconjugate


克隆類型: rabbit polyclonal


技術(shù)規(guī)格

Background:

This gene encodes a pyrin-like protein containing a pyrin domain, a nucleotide-binding site (NBS) domain, and a leucine-rich repeat (LRR) motif. This protein interacts with the apoptosis-associated speck-like protein PYCARD/ASC, which contains a caspase recruitment domain, and is a member of the NALP3 inflammasome complex. This complex functions as an upstream activator of NF-kappaB signaling, and it plays a role in the regulation of inflammation, the immune response, and apoptosis. Mutations in this gene are associated with familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome, and neonatal-onset multisystem inflammatory disease (NOMID). Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. Alternative 5' UTR structures are suggested by available data; however, insufficient evidence is available to determine if all of the represented 5' UTR splice patterns are biologically valid.

Applications:

ELISA, IHC

Name of antibody:

NLRP3

Immunogen:

Fusion protein of human NLRP3

Full name:

NLR family, pyrin domain containing 3

Synonyms:

AII; AVP; FCU; MWS; FCAS; CIAS1; NALP3; C1orf7; CLR1.1; PYPAF1; AGTAVPRL

SwissProt:

Q96P20

ELISA Recommended dilution:

1000-2000

IHC positive control:

Human esophagus cancer and human thyroid cancer

IHC Recommend dilution:

15-50